Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Videos | Pharmaceuticals

VIDEO: Icosapent Ethyl Significantly Reduces Coronary Plaque in EVAPORATE Study

Matthew Budoff, M.D., director of cardiovascular CT at The Lundquist Institute, and professor of medicine at the David ...

September 10, 2020

Icosapent ethyl (Vascepa) demonstrated significant, 17 percent regression of low attenuation plaque (LAP) volume on multidetector computed tomography (MDCT) compared with placebo over 18 months in the EVAPORATE Trial

News | Pharmaceuticals

Icosapent Ethyl Significantly Reduces Coronary Plaque in EVAPORATE Study

September 10, 2020 - Icosapent ethyl (Vascepa) demonstrated significant, 17 percent regression of low attenuation plaque ...

September 10, 2020

News | Coronavirus (COVID-19)

First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients

September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensin ...

September 08, 2020

Examples of pulmonary embolism clots caused by COVID-19 seen on a chest CT. From the journal Radiology

News | Coronavirus (COVID-19)

Possible Blood Clotting Mechanism in COVID-19 Found

September 3, 2020 — Why so many COVID-19 (SARS-CoV-2) patients get blood clots (thrombosis) remains uncertain. But ...

September 03, 2020

Tailor PCI trial showed genetic testing may play a role in personalizing antiplatelet therapy after PCI.

News | Antiplatelet and Anticoagulation Therapies

Trial Shows Benefit of Using Genetic Testing to Tailor Antiplatelet Therapy

September 2, 2020 — An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce by ...

September 02, 2020

Dapagliflozin (Farxiga) heart failure drug performs very will to improve outcomes for patients with chronic kidney disease.

News | Pharmaceuticals

Dapagliflozin Meets All Endpoints to Treat Chronic Kidney Disease

July 28, 2020 — AstraZeneca's heart failure medication dapagliflozin (Farxiga) significantly reduced the worsening of ...

July 28, 2020

News | Stents

CeloNova Completes Enrollment of First Randomized 14-Day DAPT Trial For a Stent

July 24, 2020 — CeloNova BioSciences Inc. announced it successfully completed enrollment of the COBRA REDUCE randomized ...

July 24, 2020

The FDA has determined chloroquine and hydroxychloroquine are not effective at treating novel coronavirus and revoked its earlier emergency use authorization (EUA) for the drugs to be used in COVID-19 patients. FDA says hydroxychloroquine does not work to treat COVID-19.Getty Images #COVID19 #COVID19update #SARSCoV2

Feature | Coronavirus (COVID-19) | Dave Fornell, Editor

FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine for COVID-19

June 15, 2020 — The U.S. Food and Drug Administration (FDA) today revoked the emergency use authorization (EUA) that ...

June 15, 2020

Videos | Coronavirus (COVID-19)

VIDEO: Why QT-prolongation Occurs in COVID-19 Patients on Hydroxychloroquine and Azithromycin

Interview with Andrew D. Krahn, M.D.,FHRS, head of the division of cardiology at St. Paul’s Hospital, and professor of ...

May 28, 2020

Feature | Coronavirus (COVID-19)

WHO Database Shows Serious Health Impact of Hydroxychloroquine and Azithromycin Being Used to Treat COVID-19

May 27, 2020 — Two of the front-line drugs being used to treat COVID-19 (SARS-CoV-2) patients are hydroxychloroquine and ...

May 27, 2020

Videos | Coronavirus (COVID-19)

VIDEO: Overview of Hydroxychloroquine and FDA Warning in its use to Treat COVID-19

Marianne Pop, Pharm.D., BCPS, a clinical pharmacist and clinical assistant professor with the regional pharmacy program ...

May 18, 2020

Icosapent Ethyl (Vascepa) significantly Reduces Revascularizations in Statin Patients in the REDUCE-IT REVASC analyses presented as a late-breaking study at SCAI 2020. Photo by Dave Fornell

News | Pharmaceuticals

Icosapent Ethyl Significantly Reduces Revascularizations in Statin Patients

May 17, 2020 – Patients with high lipid levels have an increased risk for ischemic events, despite statin therapy ...

May 17, 2020

The Boston Scientific Synergy stent uses a unique abluminal, bioresorbable drug-carrier polymer that dissolves after the vessel wall has healed months after the stent is implanted. Stent polymers have been implicated in cases of late-stent thrombosis, which required patients with DES to stay on dual antiplatelet therapy (DAPT). This study looked at using the device as a way to shorten DAPT duration. #SCAI2020

News | Stents

TWILIGHT Trial Substudy Examines Bioabsorbable Polymer vs. Durable Polymer Drug-Eluting Stents in High-Risk PCI

May 17, 2020 – A new study sought to reveal whether drug-eluting stents (DES) coated with bioabsorbable polymer (BP) ...

May 17, 2020

News | EP Lab

Etripamil Nasal Spray Does Not Meet Primary Endpoint in Treating Supraventricular Tachycardia

May 13, 2020 — The patient-administered nasal spray drug etripamil did not meet its primary endpoint in treating ...

May 13, 2020

News | Atrial Fibrillation

High Incidence Of Silent Brain Infarcts Found in Anticoagulated Atrial Fibrillation Patients

May 8, 2020 – A new clinical study found that patients with atrial fibrillation (AF) experienced a high incidence of ...

May 08, 2020